Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Laropiprant (MK-0524) 是 DP receptor 的选择性拮抗剂,Ki 为 0.57 nM,对 TP 受体的 Ki 为 2.95 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 372 | 现货 | ||
2 mg | ¥ 519 | 现货 | ||
5 mg | ¥ 818 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,320 | 现货 | ||
50 mg | ¥ 3,690 | 现货 | ||
100 mg | ¥ 5,490 | 现货 | ||
500 mg | ¥ 10,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 883 | 现货 |
产品描述 | Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM). |
靶点活性 | DP/DP1 receptor:0.57 nM (ki), TP receptor:2.95 nM (ki) |
体外活性 | Laropiprant blocks DP receptor-dependent enhance in VASP phosphorylation, as well as inhibition of P-selectin expression, GPIIb/IIIa activation, and in vitro thrombus formation. Laropiprant antagonizes the increased platelet aggregation by TP and EP3 receptor activation. Laropiprant (1 μM) induces a significant inhibition of the aggregation but still counteracts the pronounced inhibition caused by PGD2 (30 nM) and BW245c (3 nM). Laropiprant (10 μM) and niacin inhibit in vitro thrombus formation[2]. |
别名 | MK-0524 |
分子量 | 435.9 |
分子式 | C21H19ClFNO4S |
CAS No. | 571170-77-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (229.41 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2941 mL | 11.4705 mL | 22.941 mL | 57.3526 mL |
5 mM | 0.4588 mL | 2.2941 mL | 4.5882 mL | 11.4705 mL | |
10 mM | 0.2294 mL | 1.1471 mL | 2.2941 mL | 5.7353 mL | |
20 mM | 0.1147 mL | 0.5735 mL | 1.1471 mL | 2.8676 mL | |
50 mM | 0.0459 mL | 0.2294 mL | 0.4588 mL | 1.1471 mL | |
100 mM | 0.0229 mL | 0.1147 mL | 0.2294 mL | 0.5735 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Laropiprant 571170-77-9 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor DP receptor inhibit metabolismacyl MK0524 MK-0524 Inhibitor MK 0524 pharmacokinetics glucuronide inhibitor